LinkedIn (NYSE:LNKD): William Blair views LinkedIn’s follow-on offering, announced Tuesday night, as the company taking advantage of the recent run-up in its share price. The firm said there is no specific need for the additional capital. William Blair keeps a Market Perform rating on the stock.
MetLife (NYSE:MET): Barclays upgraded MetLife to Overweight from Equal Weight based on benefits from higher U.S. rates, a steepening yield curve, and valuation. The price target on the shares has been raised to $58 from $54.
CBS (NYSE:CBS): Piper Jaffray believes CBS is in the early stages of content monetization and raised its price target for shares to $65 from $60 while keeping an Overweight rating on the name.
Biogen (NASDAQ:BIIB): Deutsche Bank attributes the pullback since May in shares of Biogen to concerns around the Tecfidera launch in Europe and scripts in the U.S. Deutsche Bank thinks the risk/reward is attractive on potential pipeline success and recommends using the recent selloff to buy the stock, giving shares a Buy rating with a $270 price target.